Avid Bioservices (CDMO)
(Delayed Data from NSDQ)
$7.09 USD
+0.19 (2.68%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $7.08 -0.01 (-0.07%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Avid Bioservices, Inc. [CDMO]
Reports for Purchase
Showing records 41 - 60 ( 62 total )
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
Biologic Manufacturing Sets New Quarter Record; Positive Industry Read-Throughs
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
Initiating Coverage at Overweight; Only CDMO Pure Play in Bioproduction
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
Initiating Coverage on Life Science Technology, Bioproduction, - Diagnostics
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
F2020 Results; Revs Are Revvin''; Prepping for Capacity Expansion
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
F3Q20 Results; Business Continues to Grow Despite Temporary Equipment Challenge; Target Adjusted to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
F2Q20 Results; CDMO Business Keeps Plugging Away.
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
F1Q20 Results; Avid Continues to Grow Business and Validation Among CDMOs
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
Looking Glass Into the Future? Increasing CDMO Demand Could Certainly Point to Fruitful Outcomes for Avid; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
No Surprises Here as Business Model Expands Meaningfully; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
F2019 Results; Business Continues to Solidify; New Business and Expanding Current Business Lead Drivers
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
Sudden Surprise and Short-Term Instability; Investment Case Unchanged
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
F3Q19 Results; Increasing Margins, Halozyme Steps Up Again, and Growing Revenue; Works for Us
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
Blocking and Tackling Continues to Bolster Encouraging 2019 Outlook
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
F2Q19 Results; Continuing to Build CDMO Leadership
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
F1Q19 Results; Business Development Continues to Ramp and Reap Rewards; Target Increased to $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J